Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Melanie J Plastini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Lewy Body Disease, Biomarkers, alpha-Synuclein. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Objective
More than half of neurodegenerative disease patients have multiple pathologies at autopsy; however, most receive one diagnosis during life. We used the α‐synuclein seed amplification assay (αSyn‐SAA) and CSF biomarkers for amyloidosis and Alzheimer's disease (AD) neuropathological change (ADNC) to determine the frequency of co‐pathologies in participants clinically diagnosed with Lewy body (LB) disease or AD.
Methods
Using receiver operating characteristic analyses on retrospective CSF samples from 150 participants determined αSyn‐SAA accuracy, sensitivity, and specificity for identifying clinically defined LB disease and predicting future change in clinical diagnosis. CSF biomarkers helped determine the frequency of concomitant Lewy body pathology, ADNC, and/or amyloidosis in participants with LB disease and AD, across clinical spectra.
Results
Following a decade‐long follow‐up, the clinically or autopsy‐defined diagnosis changed for nine participants. αSyn‐SAA demonstrated improved accuracy (91.3%), sensitivity (89.3%), and specificity (93.3%) for identifying LB disease compared to all non‐LB disease, highlighting the limitations of clinical diagnosis alone. When examining biomarkers of co‐pathology, amyloidosis was present in 18%, 48%, and 71% ( χ 2 (2) = 13.56, p = 0.001) and AD biomarkers were present in 0%, 8.7%, and 42.9% ( χ 2 (2) = 18.44, p < 0.001) of LB disease participants with different stages of cognitive impairment respectively. Co‐occurring biomarkers for αSyn‐SAA and amyloidosis were present in 12% and 14% of AD compared to 43% and 57% LB disease participants with different stages of cognitive impairment ( χ 2 (3) = 13.87, p = 0.003).
Interpretation
Our study shows that using a combination of αSyn‐SAA and AD biomarkers can identify people with αSyn, ADNC, and co‐pathology better and earlier than traditional clinical diagnostic criteria alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
- Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA.
- Amprion Clinical Laboratory, San Diego, California, USA.
- Chan Zuckerberg Biohub, San Francisco, California, 94158, USA.
- Pharma Research and Early Development, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
ORCID-Profile: Melanie J Plastini, Edward N Wilson, Marian Shahid-Besanti, Kathleen L Poston
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Alzheimer's Association
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Plastini, M. J., Abdelnour, C., Young, C. B., Wilson, E. N., Shahid-Besanti, M., Lamoureux, J., Andreasson, K. I., Kerchner, G. A., Montine, T. J., Henderson, V. W., & Poston, K. L. (2024). Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52034
Vancouver
Plastini MJ, Abdelnour C, Young CB, Wilson EN, Shahid-Besanti M, Lamoureux J, et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52034
BibTeX
@article{Plastini2024,
author = {Plastini, Melanie J and Abdelnour, Carla and Young, Christina B and Wilson, Edward N and Shahid-Besanti, Marian and Lamoureux, Jennifer and Andreasson, Katrin I and Kerchner, Geoffrey A and Montine, Thomas J and Henderson, Victor W and Poston, Kathleen L},
title = {Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52034}
}
EUVIMED